000300282 001__ 300282
000300282 005__ 20250408112605.0
000300282 0247_ $$2doi$$a10.3389/fonc.2025.1549683
000300282 0247_ $$2pmid$$apmid:40190565
000300282 0247_ $$2pmc$$apmc:PMC11968665
000300282 037__ $$aDKFZ-2025-00735
000300282 041__ $$aEnglish
000300282 082__ $$a610
000300282 1001_ $$0P:(DE-He78)eaf20c5a3181cca70305b4a16d7f20ec$$aKanatoula, Danai$$b0$$eFirst author$$udkfz
000300282 245__ $$aEffective treatment of refractory, locally metastatic squamous cell carcinoma of the leg with isolated limb perfusion: a case report with unexpected long progression-free interval.
000300282 260__ $$aLausanne$$bFrontiers Media$$c2025
000300282 3367_ $$2DRIVER$$aarticle
000300282 3367_ $$2DataCite$$aOutput Types/Journal article
000300282 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1744101346_1432
000300282 3367_ $$2BibTeX$$aARTICLE
000300282 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000300282 3367_ $$00$$2EndNote$$aJournal Article
000300282 500__ $$a#EA:A370#LA:A370#
000300282 520__ $$aNon-melanoma skin cancer (NMSC) is one of the most commonly diagnosed human malignancies and its incidence is steadily increasing. Locally advanced cutaneous squamous cell carcinoma of the extremities that is refractory to standard therapies can be challenging to treat, with amputation of the limb being the ultima ratio treatment. Here we present a 67-year-old female patient with metastatic SCC of the leg refractory to standard therapies who was effectively treated with isolated limb perfusion and is free of any sign of relapse since more than 3 years. This case report provides a brief review of the recent literature on isolated limb perfusion and how this effective treatment can preserve the patient's quality of life by avoiding radical surgery and its negative consequences through limb salvage.
000300282 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000300282 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000300282 650_7 $$2Other$$aSCC
000300282 650_7 $$2Other$$aisolated limb perfusion
000300282 650_7 $$2Other$$arhTNFα
000300282 650_7 $$2Other$$asquamous cell carcinoma
000300282 650_7 $$2Other$$atreatment
000300282 7001_ $$0P:(DE-He78)843d6e8cab17c2120fe6638b22e674e2$$aWohlfeil, Sebastian A$$b1$$udkfz
000300282 7001_ $$aJakob, Jens$$b2
000300282 7001_ $$aHohenberger, Peter$$b3
000300282 7001_ $$0P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aUtikal, Jochen$$b4$$eLast author$$udkfz
000300282 773__ $$0PERI:(DE-600)2649216-7$$a10.3389/fonc.2025.1549683$$gVol. 15, p. 1549683$$p1549683$$tFrontiers in oncology$$v15$$x2234-943X$$y2025
000300282 909CO $$ooai:inrepo02.dkfz.de:300282$$pVDB
000300282 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)eaf20c5a3181cca70305b4a16d7f20ec$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000300282 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)843d6e8cab17c2120fe6638b22e674e2$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000300282 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000300282 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000300282 9141_ $$y2025
000300282 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT ONCOL : 2022$$d2024-12-18
000300282 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000300282 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000300282 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-08T17:01:20Z
000300282 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-08T17:01:20Z
000300282 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-08-08T17:01:20Z
000300282 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-08-08T17:01:20Z
000300282 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000300282 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000300282 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-18
000300282 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000300282 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000300282 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000300282 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-18
000300282 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-18
000300282 9202_ $$0I:(DE-He78)A370-20160331$$kA370$$lKKE Dermatoonkologie$$x0
000300282 9201_ $$0I:(DE-He78)A370-20160331$$kA370$$lKKE Dermatoonkologie$$x0
000300282 9200_ $$0I:(DE-He78)A370-20160331$$kA370$$lKKE Dermatoonkologie$$x0
000300282 980__ $$ajournal
000300282 980__ $$aVDB
000300282 980__ $$aI:(DE-He78)A370-20160331
000300282 980__ $$aUNRESTRICTED